MCID: ANX010
MIFTS: 72

Anxiety

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anxiety

MalaCards integrated aliases for Anxiety:

Name: Anxiety 53 12 28 40 69
Anxiety Disorders 51 41 69
Anxiety Disorder 12 14
Anxiety State 12 69
Anxiety Neurosis 69

Classifications:



External Ids:

OMIM 53 607834
Disease Ontology 12 DOID:2030
ICD10 32 F41.9 F41.8
ICD9CM 34 300.09
MeSH 41 D001008
NCIt 46 C2878
MedGen 39 C0003467

Summaries for Anxiety

OMIM : 53 Human personality is shaped by genetic and environmental factors, and evidence suggests that the genetic component is highly complex, polygenic, and epistatic. Genetic factors are thought to contribute to 40 to 60% of trait variance. Molecular genetics has tried to identify specific genes for quantitative traits, called quantitative trait loci (QTLs). The QTL concept suggests that complex personality traits or dimensions are not attributable to single genes, but to multiple interacting genes (Reif and Lesch, 2003). Fullerton et al. (2003) stated that psychologists were in agreement that the wide variation in human personalities can be explained by a small number of personality factors, including neuroticism (a measure of emotional stability), which manifests at one extreme as anxiety, depression, moodiness, low self-esteem, and diffidence. They cited a number of studies that had described a relationship between high scores on measures of neuroticism and major depressive disorder. They also noted that theoretical studies had suggested that large samples of randomly ascertained sibs could be used to ascertain phenotypically extreme individuals and thereby increase power to detect genetic linkage in complex traits. See also panic disorder (PAND1; 167870), which is a subtype of anxiety disorder. (607834)

MalaCards based summary : Anxiety, also known as anxiety disorders, is related to generalized anxiety disorder and phobic disorder, and has symptoms including sleeplessness, agitation and nervousness. An important gene associated with Anxiety is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Ethanol and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

MedlinePlus : 40 Fear and anxiety are part of life. You may feel anxious before you take a test or walk down a dark street. This kind of anxiety is useful - it can make you more alert or careful. It usually ends soon after you are out of the situation that caused it. But for millions of people in the United States, the anxiety does not go away, and gets worse over time. They may have chest pains or nightmares. They may even be afraid to leave home. These people have anxiety disorders. Types include Panic disorder Obsessive-compulsive disorder Post-traumatic stress disorder Phobias Generalized anxiety disorder Treatment can involve medicines, therapy or both. NIH: National Institute of Mental Health

Wikipedia : 72 Anxiety is an emotion characterized by an unpleasant state of inner turmoil, often accompanied by... more...

Related Diseases for Anxiety

Diseases related to Anxiety via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 515)
# Related Disease Score Top Affiliating Genes
1 generalized anxiety disorder 33.5 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
2 phobic disorder 33.0 COMT HTR1A MAOA PTK7 SLC6A4
3 phobia, specific 32.5 COMT MAOA
4 agoraphobia 32.5 CCKBR HTR1A MAOA PTK7 SLC6A4
5 alcohol abuse 32.2 BDNF CNR1 SLC6A4
6 eating disorder 32.1 BDNF CNR1 COMT HTR2C SLC6A4
7 irritable bowel syndrome 31.9 CRH CRHR1 SLC6A4 TPH1
8 bulimia nervosa 1 31.8 BDNF COMT HTR2A MAOA SLC6A4
9 postpartum depression 31.8 BDNF COMT CRH HTR1A MAOA SLC6A4
10 autism spectrum disorder 31.5 BDNF COMT HTR2A MAOA SLC6A4 TPH2
11 post-traumatic stress disorder 31.3 BDNF CNR1 COMT CRH HTR2A MAOA
12 obsessive-compulsive disorder 31.1 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
13 alexithymia 31.0 COMT HTR1A SLC6A4
14 panic disorder 30.9 BDNF CCKBR COMT CRH CRHR1 HTR1A
15 migraine with or without aura 1 30.8 CNR1 COMT CYP2D6 HTR1A HTR2A HTR2C
16 bipolar disorder 30.6 BDNF COMT CRH HTR1A HTR2A HTR2C
17 chronic pain 30.5 CNR1 COMT
18 conduct disorder 30.5 COMT MAOA SLC6A4 TPH1
19 bulimia nervosa 2 30.4 BDNF COMT CRH HTR2A SLC6A4
20 premature ejaculation 30.4 COMT HTR1A HTR2C SLC6A4
21 antisocial personality disorder 30.4 COMT MAOA SLC6A4
22 dysthymic disorder 30.4 HTR2A MAOA SLC6A4
23 tobacco addiction 30.3 COMT HTR2A MAOA TPH1
24 parkinson disease, late-onset 30.3 BDNF CNR1 COMT CYP2D6 HTR1A HTR2A
25 oppositional defiant disorder 30.2 COMT MAOA SLC6A4 TPH2
26 substance abuse 30.2 BDNF COMT CYP2D6 MAOA SLC6A4
27 pathological gambling 30.1 HTR2A MAOA SLC6A4
28 schizoaffective disorder 30.0 BDNF COMT HTR2A SLC6A4
29 drug dependence 30.0 BDNF CNR1 CRH OPRL1 SLC6A4
30 autism 30.0 BDNF COMT HTR1A HTR2A MAOA SLC6A4
31 temporal lobe epilepsy 30.0 BDNF HTR1A TSPO
32 bipolar i disorder 30.0 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
33 substance dependence 29.8 BDNF CNR1 CYP2D6 MAOA SLC6A4
34 schizophrenia 29.8 BDNF CNR1 COMT CYP2D6 CYP3A4 HTR1A
35 personality disorder 29.8 BDNF COMT HTR1A HTR2A HTR2C MAOA
36 cannabis abuse 29.7 BDNF CNR1
37 narcolepsy 29.7 COMT HTR2A NPS TPH1
38 psychotic disorder 29.6 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
39 paranoid schizophrenia 29.4 BDNF COMT HTR2A MAOA SLC6A4 TPH2
40 early-onset schizophrenia 29.4 BDNF COMT HTR2A MAOA SLC6A4
41 chronic fatigue syndrome 29.3 COMT CRH HTR1A MAOA NR3C1 SLC6A4
42 central nervous system disease 29.3 BDNF CNR1 CYP2D6 HTR2A SLC6A4
43 attention deficit-hyperactivity disorder 29.2 BDNF COMT CYP2D6 HTR1A HTR2A HTR2C
44 mood disorder 28.9 BDNF COMT CRH CRHR1 HTR1A HTR2A
45 borderline personality disorder 28.9 BDNF COMT HTR1A HTR2A HTR2C MAOA
46 alcohol dependence 28.8 BDNF CNR1 COMT CRHR1 HTR1A HTR2A
47 serotonin syndrome 28.8 CYP2D6 CYP3A4 HTR1A HTR2A MAOA SLC6A4
48 major depressive disorder 28.8 BDNF COMT CRH CRHR1 CYP2D6 HTR1A
49 endogenous depression 28.7 BDNF CRH CRHR1 HTR1A HTR2A MAOA
50 disease of mental health 28.4 BDNF CNR1 COMT CRH CYP2D6 HTR1A

Comorbidity relations with Anxiety via Phenotypic Disease Network (PDN): (show top 50) (show all 80)


Acute Cor Pulmonale Acute Cystitis
Acute Stress Disorder Adjustment Disorder
Allergic Rhinitis Atrophic Gastritis
Atypical Depressive Disorder Basilar Artery Insufficiency
Benign Essential Hypertension Borderline Personality Disorder
Bronchiectasis Bronchitis
Bronchopneumonia Cerebrovascular Disease
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Rhinitis Conn's Syndrome
Conversion Disorder Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dyskinesia of Esophagus Dysthymic Disorder
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Histrionic Personality Disorder
Hyperlipoproteinemia, Type Iv Hypertension, Essential
Hypertensive Encephalopathy Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Irritable Bowel Syndrome
Ischemic Heart Disease Labyrinthitis
Major Depressive Disorder Malignant Essential Hypertension
Meniere Disease Migraine with or Without Aura 1
Mitral Valve Disease Mood Disorder

Graphical network of the top 20 diseases related to Anxiety:



Diseases related to Anxiety

Symptoms & Phenotypes for Anxiety

Clinical features from OMIM:

607834

UMLS symptoms related to Anxiety:


sleeplessness, agitation, nervousness, feeling jittery, feeling tense, anxiety symptoms, mental and behavioral signs and symptoms

MGI Mouse Phenotypes related to Anxiety:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 OPRL1 SLC6A4 TPH1 TPH2 TSPO BDNF
2 homeostasis/metabolism MP:0005376 10.24 NR3C1 OPRL1 SLC6A4 TPH1 TPH2 TSPO
3 cardiovascular system MP:0005385 10.2 COMT CRHR1 HTR1A MAOA NR3C1 PTK7
4 growth/size/body region MP:0005378 10.14 SLC6A4 TPH1 TPH2 TSPO CRH HTR2C
5 nervous system MP:0003631 10.1 BDNF CCKBR CNR1 COMT CRH CRHR1
6 endocrine/exocrine gland MP:0005379 10.09 BDNF CCKBR COMT CRH CRHR1 HTR2A
7 integument MP:0010771 10.02 BDNF CCKBR CNR1 CRH HTR2C NR3C1
8 adipose tissue MP:0005375 9.97 CNR1 CRH HTR2C NR3C1 TPH1 TPH2
9 no phenotypic analysis MP:0003012 9.7 BDNF CNR1 CRH CRHR1 HTR1A NR3C1
10 normal MP:0002873 9.61 OPRL1 SLC6A4 TPH2 TSPO BDNF CNR1
11 respiratory system MP:0005388 9.23 BDNF COMT CRH CRHR1 NR3C1 PTK7

Drugs & Therapeutics for Anxiety

Drugs for Anxiety (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1335)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
6
Mannitol Approved, Investigational Phase 4,Phase 2 69-65-8 6251 453
7
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 60142-96-3 3446
8
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
9
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 298-46-4 2554
10
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-36-2 446220 5760
11
Imipramine Approved Phase 4,Phase 3 50-49-7 3696
12
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1 59-92-7 6047
13
Heroin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 561-27-3 5462328
14
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 89594 942
15
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 439-14-5 3016
16
Aspirin Approved, Vet_approved Phase 4,Early Phase 1 50-78-2 2244
17
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757
18
Etoposide Approved Phase 4,Phase 3,Phase 2,Early Phase 1 33419-42-0 36462
19
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
20
Fexofenadine Approved, Investigational Phase 4,Phase 1 83799-24-0 3348
21
Irinotecan Approved, Investigational Phase 4,Phase 3 97682-44-5, 100286-90-6 60838
22
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1 154598-52-4 64139
23
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 51-43-4 5816
24
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
25
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59467-70-8 4192
26
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
27
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1 15307-86-5 3033
28
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
29
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 103-90-2 1983
30
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
31
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15687-27-1 3672
32
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 99-66-1 3121
33
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51384-51-1, 37350-58-6 4171
34
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
35
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
36
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
37
Atropine Approved, Vet_approved Phase 4,Phase 3 5908-99-6, 51-55-8 174174
38
Rasagiline Approved Phase 4,Phase 2 136236-51-6 3052776
39
Rocuronium Approved Phase 4,Phase 3 119302-91-9, 143558-00-3 441290
40
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
41
Tibolone Approved, Investigational Phase 4,Phase 1 5630-53-5
42
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
43
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 525-66-6 4946
44
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
45
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 657311 5754
46
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 36505-84-7 2477
47
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
48
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 58-00-4, 41372-20-7 6005
49
Haloperidol Approved Phase 4,Phase 3,Phase 2 52-86-8 3559
50
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585

Interventional clinical trials:

(show top 50) (show all 9484)

# Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children Unknown status NCT02545634 Phase 4
4 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
5 The Effect of Sihogayonggolmoryeo-tang on the Anxiety of Hwa-byung Unknown status NCT01362114 Phase 4 SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
6 Preoperative Anxiety and Postoperative Pain in Children Unknown status NCT00643032 Phase 4
7 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
8 Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial Unknown status NCT02243826 Phase 4 50:50 mixture of nitrous oxide/oxygen
9 Assessment of the Effectiveness of a Program of Preparation to Pregnancy and Delivery Unknown status NCT01155804 Phase 4
10 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
11 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
12 Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy Unknown status NCT01121055 Phase 4 Lorazepam;Control
13 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
14 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
15 Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD) Unknown status NCT01990937 Phase 4 Oral midazolam
16 Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Unknown status NCT02042001 Phase 4 Immediate switch to TDF/FTC/RPV;Switch to TDF/FTC/RPV after 12 weeks
17 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
18 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
19 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
20 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
21 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
22 Prevention of Posttraumatic Stress Disorder (PTSD) With Diazepam Unknown status NCT01221883 Phase 4 Diazepam
23 Customized Acoustic Stimulation for Long Term Medical Benefit for the Relief of Tinnitus and Hyperacusis Unknown status NCT00730834 Phase 4
24 Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients Unknown status NCT02134093 Phase 4 Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium;Dexmedetomidine;Normal saline;Maintenance of anesthesia , propofol, remifentanil,vecuronium
25 Clinical Trial to Evaluate the Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
26 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
27 Impact of Probiotic Preparation VSL#3 on Infants Colics Unknown status NCT01869426 Phase 4
28 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO
29 The Use of Oral N-Acetyl Cysteine for the Treatment of Chronic Sinonasal Symptoms Unknown status NCT00866866 Phase 4 N-Acetyl Cysteine;Placebo
30 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
31 Climacteric Clinical Trial : the Use of Complementary Therapy and Hormonal Replacement Unknown status NCT00617500 Phase 4 Hormones
32 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4 METHYLPHENIDATE
33 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
34 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
35 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
36 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
37 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
38 Paracervical Block for Pain Control in First Trimester Abortion Unknown status NCT01094366 Phase 4
39 Ultrasound Guided Cannulation of Dialysis Fistulas Unknown status NCT01163981 Phase 4
40 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
41 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
42 Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain Unknown status NCT02125968 Phase 4
43 Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder Unknown status NCT00134446 Phase 4
44 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
45 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
46 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
47 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
48 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
49 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
50 Juvenile Bipolar Disorder Outpatient Program Unknown status NCT01000402 Phase 4 Psychopharmacotherapy

Search NIH Clinical Center for Anxiety

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: anxiety disorders

Genetic Tests for Anxiety

Genetic tests related to Anxiety:

# Genetic test Affiliating Genes
1 Anxiety 28 SLC6A4

Anatomical Context for Anxiety

MalaCards organs/tissues related to Anxiety:

38
Breast, Brain, Testes, Heart, Prostate, Lung, Spinal Cord

Publications for Anxiety

Articles related to Anxiety:

(show top 50) (show all 2812)
# Title Authors Year
1
The influence of alexithymia on mobile phone addiction: The role of depression, anxiety and stress. ( 28926906 )
2018
2
Facial gender but not emotion distinguishes neural responses of 10- to 13-year-old children with social anxiety disorder from healthy and clinical controls. ( 29452149 )
2018
3
Psychiatrists' treatment preferences for generalized anxiety disorder. ( 29266492 )
2018
4
A Review of Evidence Based Treatments for Transgender Youth Diagnosed with Social Anxiety Disorder. ( 29445772 )
2018
5
Anxiety and Depression: A Cross-sectional Survey among Parents of Children with Cancer. ( 29440813 )
2018
6
Difficulty concentrating in generalized anxiety disorder: An evaluation of incremental utility and relationship to worry. ( 29175616 )
2018
7
Pharmacological treatment of anxiety disorders in children and adolescents: a review for practitioners. ( 29441280 )
2018
8
The Relationship between Anxiety, External Structure, Behavioral History and Becoming Locked into Restricted and Repetitive Behaviors in Autism Spectrum Disorder. ( 29436876 )
2018
9
Anxiety and depression in general practice outpatients: the long-term change process. ( 29445294 )
2018
10
Changes in perceived centrality of anxious events following cognitive behavioral therapy for social anxiety disorder and panic disorder. ( 29425950 )
2018
11
Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study. ( 29433063 )
2018
12
Predicting the Effectiveness of Work-Focused CBT for Common Mental Disorders: The Influence of Baseline Self-Efficacy, Depression and Anxiety. ( 29450678 )
2018
13
Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. ( 29300754 )
2018
14
Differential anxiety-like responses in NOD/ShiLtJ and C57BL/6J mice following experimental autoimmune encephalomyelitis induction and oral gavage. ( 29444620 )
2018
15
Blood phenylalanine instability strongly correlates with anxiety in phenylketonuria. ( 29326880 )
2018
16
Client reflections on confirmation and disconfirmation of expectations in cognitive behavioral therapy for generalized anxiety disorder with and without motivational interviewing. ( 29357757 )
2018
17
Peripheral proinflammatory cytokines in Chinese patients with generalised anxiety disorder. ( 28886500 )
2018
18
Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. ( 29451967 )
2018
19
How do anxiety affect CD34 and CD3 cells in allogeneic peripheral blood stem cell transplantation? ( 29439917 )
2018
20
The effect of panic disorder versus anxiety sensitivity on event-related potentials during anticipation of threat. ( 29291580 )
2018
21
Identification of Distinct Latent Classes Related to Sleep, PTSD, Depression, and Anxiety in Individuals Diagnosed With Severe Alcohol Use Disorder. ( 29377714 )
2018
22
The relationship among preconception depression, anxiety, and social support of the reproductive-aged women in China. ( 29445909 )
2018
23
Dental anxiety and influencing factors: A cross-sectional questionnaire-based survey. ( 29442080 )
2018
24
Anxiety and anger of homeless people coping with dental care. ( 29446849 )
2018
25
A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. ( 29153755 )
2018
26
Depressive Disorder, Anxiety Disorder and Chronic Pain: Multiple Manifestations of a Common Clinical and Pathophysiological Core. ( 29428122 )
2018
27
The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug NaA^ve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients. ( 29397670 )
2018
28
Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. ( 29383439 )
2018
29
Endometriosis alters brain electro-physiology, gene expression and increased pain sensitization, anxiety, and depression in female mice. ( 29425272 )
2018
30
Risk Factors, Clinical Presentations, and Functional Impairments for Generalized Anxiety Disorder in Military Personnel and the General Population in Canada. ( 29304289 )
2018
31
Abnormal spontaneous brain activity in patients with generalized anxiety disorder revealed by resting-state functional MRI. ( 29406370 )
2018
32
trans-Resveratrol ameliorates anxiety-like behaviors and fear memory deficits in a rat model of post-traumatic stress disorder. ( 29373817 )
2018
33
Polysomnography-Detected Bruxism in Children is Associated With Somatic Complaints But Not Anxiety. ( 29198292 )
2018
34
Olfactory processing in bipolar disorder, major depression, and anxiety. ( 29441710 )
2018
35
Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder. ( 29348532 )
2018
36
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
37
When Did Coloring Books Become Mindful? Exploring the Effectiveness of a Novel Method of Mindfulness-Guided Instructions for Coloring Books to Increase Mindfulness and Decrease Anxiety. ( 29441038 )
2018
38
Anxiety is not enough to drive me away: A latent profile analysis on math anxiety and math motivation. ( 29444137 )
2018
39
Affective predictors of the severity and change in eating psychopathology in residential eating disorder treatment: The role of social anxiety. ( 29384466 )
2018
40
Environmental enrichment decreases avoidance responses in the elevated T-maze and delta FosB immunoreactivity in anxiety-related brain regions. ( 29448033 )
2018
41
Investigating the psychometric properties of the revised child anxiety and depression scale (RCADS) in a non-clinical sample of Irish adolescents. ( 29447056 )
2018
42
Worry amplifies theory-of-mind reasoning for negatively valenced social stimuli in generalized anxiety disorder. ( 29254067 )
2018
43
Association Analysis of the Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Gender with Efficacy of Antidepressants in the Chinese Han Population with Generalized Anxiety Disorder. ( 29446659 )
2018
44
COPD in Primary Care: Key Considerations for Optimized Management: Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management. ( 29443332 )
2018
45
Psychoactive substance abuse and dependence and its association with anxiety disorders: a population-based study of young adults in Brazil. ( 29451585 )
2018
46
Anxiety and Depression in Patients with Traumatic Spinal Cord Injury: A Nationwide Population-Based Cohort Study. ( 28081205 )
2017
47
Depression, sleep disturbances and anxiety in patients with relapsing-remitting multiple sclerosis: a longitudinal cohort observation. ( 28953809 )
2017
48
Social anxiety and autism spectrum traits among adult FMR1 premutation carriers. ( 27102723 )
2017
49
Nitric oxide pathway genes (NOS1AP and NOS1) are involved in PTSD severity, depression, anxiety, stress and resilience. ( 28465168 )
2017
50
Using interpersonal process recall to compare patients' accounts of resistance in two psychotherapies for generalized anxiety disorder. ( 28910493 )
2017